Teva Pharmaceutical Industries (NYSE:TEVA) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) announced its earnings results on Wednesday. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01, Zacks reports. Teva Pharmaceutical Industries had a positive return on equity of 42.92% and a negative net margin of 5.73%. Teva Pharmaceutical Industries updated its FY 2025 guidance to 2.350-2.650 EPS.

Teva Pharmaceutical Industries Stock Down 13.7 %

Shares of TEVA stock traded down $2.94 during trading hours on Wednesday, hitting $18.59. 11,770,001 shares of the company were exchanged, compared to its average volume of 9,782,993. The stock has a market capitalization of $21.06 billion, a price-to-earnings ratio of -21.87, a P/E/G ratio of 1.11 and a beta of 0.73. Teva Pharmaceutical Industries has a one year low of $11.48 and a one year high of $22.80. The business's 50-day simple moving average is $19.94 and its two-hundred day simple moving average is $18.47. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Analysts Set New Price Targets

Several brokerages recently issued reports on TEVA. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an "overweight" rating in a research note on Wednesday, December 18th. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. UBS Group increased their target price on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $22.63.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares of the company's stock, valued at $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the firm's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.